New York Drug Developer's Big Money Maker had Nearly $1.74B in Sales Last Year
Thursday, January 15, 2015
Source: Albany Business Review
A drug that treats a leading cause of adult blindness had nearly $1.74 billion in net United States sales last year, and played a key role in the continued upward trajectory of Regeneron Pharmaceuticals, a New York company with about 900 workers in the Albany region.
That is according to a report by Leonard Schleifer, president and CEO of Regeneron, which has been among the fastest growing drug developers after its breakthrough with Eylea, the adult blindness drug.